Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. 2013

Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.

BACKGROUND Atypical haemolytic uraemic syndrome (aHUS) is associated with dysfunction of the alternative pathway of complement. Disease activity subsides as renal failure progresses but recurs upon renal transplantation, indicating that viable renal tissue contributes to disease activity. We present evidence of cerebrovascular occlusive disease indicating that vascular injury may occur in the absence of kidneys. METHODS A currently 12-year-old girl developed renal failure at the age of 20 months. She underwent bilateral nephrectomy and renal transplantation but lost the transplant due to recurrences. She was on haemodialysis for 7 years. At 10 years of age she developed a transient ischaemic attack. Imaging, genetic investigation and mutation characterization were performed. RESULTS Imaging demonstrated occlusion and stenosis of the carotid arteries. Two complement mutations, a novel mutation in factor B and a previously described mutation in factor I, and the H3-factor H haplotype, were identified. The factor B mutation, L433S, did not induce excessive complement activation in vitro. Measurement of C3 degradation products indicated ongoing complement activation. In spite of the patient being anephric, treatment was initiated with eculizumab, a humanized anti-C5 antibody that blocks terminal complement activation. She underwent a successful kidney transplant 9 months later and has not developed a recurrence or progression of vascular stenosis 1 year later. CONCLUSIONS The course of disease in this patient with aHUS suggests that complement-mediated vascular injury may occur in the total absence of renal tissue and overt recurrences. To our knowledge, this is the first description of eculizumab treatment in an anephric aHUS patient.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009392 Nephrectomy Excision of kidney. Heminephrectomy,Heminephrectomies,Nephrectomies
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011415 Complement Factor B A glycine-rich, heat-labile serum glycoprotein that contains a component of the C3 CONVERTASE ALTERNATE PATHWAY (C3bBb). Bb, a serine protease, is generated when factor B is cleaved by COMPLEMENT FACTOR D into Ba and Bb. C3 Proactivator,C3PA,Complement 3 Proactivator,Factor B,Properdin Factor B,Bb Fragment of Factor B,Complement Factor B Fragment, Bb,Complement Factor B, Alternative Pathway,Complement Factor B-Derived Fragment Bb,Complement Factor Ba,Complement Factor Bb,Complement Protein B,Complement Protein Factor B,Properdin Factor Ba,Properdin Factor Bb,Properdin Factor Bf,Properdin Factor Bf F1,Bb, Complement Factor,Complement Factor B Derived Fragment Bb,Factor B, Complement,Factor B, Properdin,Factor Ba, Complement,Factor Ba, Properdin,Factor Bb, Complement,Factor Bb, Properdin,Factor Bf, Properdin,Proactivator, C3,Proactivator, Complement 3,Protein B, Complement
D002561 Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others. Brain Vascular Disorders,Intracranial Vascular Disorders,Vascular Diseases, Intracranial,Cerebrovascular Diseases,Cerebrovascular Insufficiency,Cerebrovascular Occlusion,Brain Vascular Disorder,Cerebrovascular Disease,Cerebrovascular Disorder,Cerebrovascular Insufficiencies,Cerebrovascular Occlusions,Disease, Cerebrovascular,Diseases, Cerebrovascular,Insufficiencies, Cerebrovascular,Insufficiency, Cerebrovascular,Intracranial Vascular Disease,Intracranial Vascular Diseases,Intracranial Vascular Disorder,Occlusion, Cerebrovascular,Occlusions, Cerebrovascular,Vascular Disease, Intracranial,Vascular Disorder, Brain,Vascular Disorder, Intracranial,Vascular Disorders, Brain,Vascular Disorders, Intracranial
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females

Related Publications

Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
March 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
February 2012, Clinical kidney journal,
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
December 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
February 2017, Nephrology (Carlton, Vic.),
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
June 2014, Pediatric nephrology (Berlin, Germany),
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
November 2016, British journal of haematology,
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
August 2021, Clinical kidney journal,
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
March 2013, Prescrire international,
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
September 2013, Nature reviews. Nephrology,
Zivile D Békássy, and Ann-Charlotte Kristoffersson, and Mats Cronqvist, and Lubka T Roumenina, and Tania Rybkine, and Laura Vergoz, and Christophe Hue, and Veronique Fremeaux-Bacchi, and Diana Karpman
November 2012, Nature reviews. Nephrology,
Copied contents to your clipboard!